SLC6A11 and Alzheimer disease: The overall tonic inhibition revealed by blockade of GAT3/4, in CA1 was in the range of 4–6 mV, and 8–12 mV in wild-type and APPNL-F/NL-F mice, respectively (Table 4), illustrating an enhanced tonic inhibition in the AD model by 130.5 ± 0.31% (n = 9 wild-type, n = 10 APPNL-F/NL-F, ****p ≤ .0001).